Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.

In non-small cell lung cancer (NSCLC), the identification of epidermal growth factor receptor (EGFR) mutations and the parallel development of EGFR tyrosine kinase inhibitors (TKIs) have radically ...